Montreal (Canada) – February 15, 2023 – It is with great pleasure that AmorChem announces the promotion of Kevin McBride to General Partner. With over 25 years of academic and biotech research experience, Kevin joined the team in 2012 and has been a dedicated contributor to the fund ever since.
“Kevin brings a comprehensive understanding of fundamental and translational research which is a key component in setting portfolio strategy and lends him a credibility crucial to the attraction of partners, both financial and pharmaceutical. It’s a pleasure to recognise the value of his work through this new title and function,” says Ines Holzbaur, Managing Partner of AmorChem.
«I am delighted that my work has been recognised in such fashion by the Fund where I have been working for the last decade. AmorChem continues to make strides in advancing early stage life science innovation in the Province, and I believe that its significant contribution to the ecosystem has not yet fully materialised. That’s what I want to focus on in the coming years as a General Partner, alongside my colleagues in the Fund,” says Kevin McBride.
AmorChem (www.amorchem.com) is a leading early stage venture capital fund launched in 2011 in Montreal. The AmorChem team utilizes its deep understanding of fundamental science to uncover its therapeutic potential and focuses its core expertise in translational research to accelerate therapeutic drug discovery and development across a broad spectrum of disease areas. The fund capitalises on both its venture capital expertise and its entrepreneurial experience to spark the creation of start-up companies and help shape them into the next generation of biotech companies. With over $85M under management, AmorChem has financed over 30 university projects and started up several biotechnology companies from the fruits of this innovative research.